Prilenia Therapeutics
PrivateLast Round
Series B
Extension
Apr 12, 2022
Total Funding Raised
$137.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Prilenia Therapeutics is a biotechnology company that develops novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, including Huntington's disease and amyotrophic lateral sclerosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prilenia Therapeutics Comparables
Compare Prilenia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QurAlis | 79% | |
| NeuroSense Therapeutics | 78% | |
| Anavex Life Sciences | 77% | |
Prilenia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 12, 2022 | ||||
| Series B | Nov 3, 2021 | ||||
| Series A | Jun 3, 2020 | ||||
| Seed | Sep 1, 2018 |
Key People
Founding team and executive leadership
Prilenia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series B Extension, Series B |
| Forbion | Series B Extension, Series B, Series A |
| Amplitude Ventures | Series B Extension, Series B |
| Morningside Ventures | Series B, Series A |
| Genworks Health | Series A |
| ALS Investment Fund | Series B Extension, Series B |
| Sectoral | Series B Extension, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
Elisabeth (Lis) Leiderman, MD, MBA, appointed as CFO.
- Mar 13, 2026
Partnered with Ferrer for co-development and commercialization of pridopidine.
Prilenia Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Prilenia Therapeutics's valuation, stock price, and market status.